Status:
UNKNOWN
The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients
Lead Sponsor:
Queen Elizabeth II Health Sciences Centre
Conditions:
Pertussis
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.
Eligibility Criteria
Inclusion
- Aged 18-64
- BMT at the QEII Health Sciences Centre
- BMT within last 12 months
- Able to read and write English language
- Able to give consent
Exclusion
- Active infection
- Active GVHD
- Recent IVIG
- Allergy to components of vaccine
- Diphtheria or tetanus vaccination within 18 months
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00336115
Start Date
July 1 2006
End Date
May 1 2008
Last Update
October 23 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.